Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden

Autor:	Mervete Miftaraj, Joao Diogo Da Rocha Fernandes, Ann-Marie Svensson, Björn Eliasson, Mattis F. Ranthe, Ann-Charlotte Mårdby, Jan Ekelund
Rok vydání:	2020
Předmět:	Insulin degludec medicine.medical_specialty Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine Internal Medicine medicine Medical prescription Original Research GLP-1 analogue Liraglutide business.industry medicine.disease Metformin Real-world Concomitant Insulin therapy Observational study business medicine.drug
Zdroj:	Diabetes Therapy
ISSN:	1869-6961 1869-6953
Popis:	Aims To explore persistence with insulin degludec/liraglutide (IDegLira) treatment, clinical characteristics and concomitant medications in a large population of patients in clinical practice. Methods This was an observational study in patients with type 2 diabetes (n = 2432) who initiated IDegLira between 26 May 2015 and 31 December 2017. Data were obtained from Swedish nationwide registers and linked on an individual level using unique Swedish personal identifiers. Dose calculations were made for patients with ≥ 180 days between the first and last collections of IDegLira prescription. Changes in clinical parameters were evaluated as change from the last observation during 12 months prior to the initiation date until ± 90 days from the last collection of IDegLira. Results Pre-index regimens (index date being the date of filling the first prescription of IDegLira) included: multiple daily insulin injections (45.1%); insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) (19.7%); long-acting insulins (11.8%); non-injectable therapy only (11.4%); GLP-1 RA only (9.8%); and no collection of diabetes medication during the 6-month pre-index period (2.3%). The majority of patients (94 and 84%) were persistent with IDegLira at 6 and 12 months, respectively. The most commonly used concomitant medication was metformin (69.4%). Mean daily dose was 33 dose steps. Overall, there was a mean decrease in HbA1c (approx. 10 mmol/mol [1%]) and body weight (− 1.1 kg). Improvements in HbA1c were observed regardless of pre-index treatment. Conclusion After 12 months, 84% of patients were persistent on IDegLira, with improved glycaemic control and reductions in body weight. Electronic supplementary material The online version of this article (10.1007/s13300-020-00872-4) contains supplementary material, which is available to authorized users.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aded5efde633a7dd059ab4debe251cc5 https://doi.org/10.1007/s13300-020-00872-4 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.